![How FDA, Pfizer, and Flatiron Health did it Approval Of Ibrance For Men Affords A Glance At Use Of Real World Data](https://cdn.cancerletter.com/media/2019/04/RWE-web.jpg)
![How FDA, Pfizer, and Flatiron Health did it Approval Of Ibrance For Men Affords A Glance At Use Of Real World Data](https://cdn.cancerletter.com/media/2019/04/RWE-web.jpg)
Cover Story
Free
Real world data played a role in FDA's recent decision to expand the indications for Pfizer's drug Ibrance (palbociclib) to include men.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills